Peptide ProvidersDirect
the biostation logo
Unclaimed12 services cataloged

the biostation

Delray Beach, FL · Telehealth available

Visit provider website ↗

Provider overview

About the biostation

the biostation identifies Martin G. Bloom, MD, as chief medical officer, medical director, and co-founder. This listing records six current clinic addresses directly supported by official location pages and a telehealth pathway whose exact state coverage is not published. The clinic's current peptide menu is unusually broad and includes provider-advertised investigational or unclear-status compounds. Their inclusion here does not establish approval, lawful compounding, availability at every location, safety, efficacy, or suitability. No dispensing pharmacy or 503A/503B relationship is inferred.

At a glance

Market role
Direct patient-care provider
Care model
Telehealth and In person
Coverage
2 listed jurisdictions
Pharmacy pathway
Not publicly established
Medical weight managementHormone healthLongevity medicineMetabolic healthLaboratory testing

503A and 503B labels describe statutory compounding pathways or public relationships. They do not mean a compounded drug is FDA-approved or that FDA endorses a facility.

Service catalog

Programs and services

Services advertised on the provider’s public website, organized by area of care.

12 cataloged
01

Provider-advertised growth-hormone-related peptides

Service 01

Hexarelin, IGF-1 LR3, tesamorelin, and sermorelin

These compounds appear in the clinic's current peptide menu; the directory does not establish regulatory status, availability, or expected outcomes.

View provider source
02

Provider-advertised recovery compounds

Service 01

PDA and pentosan polysulfate recovery pathways

The provider lists Pentadeca Arginate and pentosan polysulfate in a recovery category without directory-side safety or efficacy claims.

View provider source
03

Medical weight management

Service 01

Retatrutide, semaglutide, and tirzepatide programs

The current menu names these metabolic compounds; retatrutide remains provider-advertised and its regulatory and prescribing status should be confirmed directly.

View provider source
04

Provider-advertised cognitive and cellular wellness

Service 01

Pinealon, Synapsin, and NAD-related care

These offerings are grouped by the provider under cognitive and stress-related care; the listing does not repeat marketing outcome claims.

View provider source
05

Provider-advertised immune-health peptides

Service 01

Thymosin and VIP

The clinic names thymosin and VIP in its peptide catalog; current formulation and availability require confirmation.

View provider source
06

Sexual health

Service 01

PT-141

PT-141 is listed as a provider-advertised sexual-function offering subject to medical evaluation.

View provider source
07

Provider-advertised skin and hair compounds

Service 01

GHK-Cu and zinc-thymulin

The current menu lists these compounds in a skin and hair category without directory-side approval or outcome claims.

View provider source
08

Provider-advertised longevity compounds

Service 01

SS-31 and epithalon

The clinic lists SS-31 and epithalon under anti-aging; inclusion is a record of provider advertising, not an endorsement or regulatory determination.

View provider source
09

Testing and ongoing care

Service 01

Diagnostic blood testing and provider review

The practice describes testing across more than 100 biomarkers followed by an in-depth provider consultation and continued monitoring.

View provider source
10

Hormone health

Service 01

Hormone replacement care for men and women

Official location pages list testosterone and broader hormone-replacement services supported by diagnostic testing.

View provider source
11

Infusion and nutrient services

Service 01

IV nutrients, injections, and glutathione

The current service catalog includes IV nutrient therapy, nutrient injections, and glutathione at participating locations.

View provider source
12

Telehealth care

Service 01

Remote consultation and ongoing monitoring

The telehealth pathway includes remote history and results review, local laboratory work, a provider consultation, a personalized plan, and continued monitoring; exact states are not published.

View provider source
Important: Inclusion does not establish availability for every patient or state, regulatory status, clinical appropriateness, safety, or effectiveness.

Evidence

Sources reviewed

Logo reproduced from the provider’s official website for identification. Logo source ↗

These links support the public facts recorded here. Provider-published information is not an independent endorsement.